Introduction
The pathological hallmark of Parkinson's disease (PD) is the death of dopaminergic neurons in the substantia nigra. This results in the characteristic clinical triad of bradykinesia, rigidity and tremor, all of which may be relieved by treatment with ~-3,4-dihydroxyphenylalanine (DOPA). Treatment is only symptomatic, however, and its efficacy wanes as dopamine-containing neurons continue to degenerate and die, and the disease to slowly progress. Options for more effective therapeutic intervention have therefore focussed on attempting to design treatments that alter the course of the disease. Success in this is dependent upon an adequate understanding of the factors contributing to neuronal death in PD.
Iron in PD
One of the first observations that may have relevance to disease aetiology is the high content of iron in PD substantia nigra [l] . This accumulation of iron appears to have some regional distribution within the substantia nigra, higher levels being found in the zona compacta -the site of greatest neuronal death [Z] . Recent studies suggest that melanin, an auto-oxidation product of dopamine, may be directly associated with the susceptibility of nigral neurons to degeneration [3] , and that the neuromelanin in PD nigral neurons contains high levels of iron [4] . Intra-nigral injection of iron causes selective damage to the substantia nigral neurons in rats [ 51. The toxic effects of 6-hydroxydopamine on dopamine-containing neurons can be prevented by the iron chelator desferrioxamine [S] . All of these observations suggest that iron may play an important role in nigral neuronal death. The toxicity of the iron within the substantia nigra is dependent upon whether it is free or bound to ferritin. One group has shown that the high levels of nigral iron in PD are paralleled by low levels (SO-75% of controls) of ferritin [6] . The implication is that a significant proportion of the iron may be available in a reactive form capable of enhancing free radical formation. Others, however, have found that both iron and ferritin were increased in PD [7] . This discrepancy may be accounted for by incomparability of patient selection criteria (see later).
The disease specificity of these changes in iron is clearly important for interpretation of their possible contribution to the cause of PD. Levels of nigral iron are increased in other neurodegenerative disorders affecting the substantia nigra, including progressive supranuclear palsy and multiple system atrophy (MSA), suggesting that this is a phenomenon secondary to neuronal degeneration. However, high iron levels are associated with increased ferritin levels in these disorders. Similar changes in iron and ferritin were also seen in the two most affected areas in Hunginton's disease, the putamen and caudate nucleus [8] and in cerebral cortex from patients with Alzheimer's disease [9] . Thus, the specificity of these changes in iron metabolism to PD seem dependent upon an imbalance in the levels of iron and ferritin. This emphasizes the importance of patient selection for these studies and could account for the contradictory results from ferritin levels in PD nigra [6, 71. 
Oxidative stress in PD
In addition to the changes in iron, there is evidence for increased oxidative damage at the time of death in PD. Early studies showed a decrease in reduced glutathione in PD [lo, 111. More recently, a decrease in the levels of polyunsaturated fatty acids together with an increase in malondialdehyde (MDA) suggested increased basal lipid peroxidation in PD substantia nigra [12] . These changes are accompanied by an increase in mitochondrial manganese-associated superoxide dismutase (SOD) [13] and possibly cytosolic SOD [14] . In situ hybridization has shown that cytosolic SOD is preferentially expressed in the neuromelanin-containing neurons of the control substantia nigra [15] , suggesting an increase in this protective enzyme in response to increased free radical generation in these cells. It is unclear whether these changes of oxidative damage are paralleled in other tissues: serum MDA [16] and vitamin A [17] were unchanged in PD patients but total SOD was increased [18] . There was no difference in the level of the antioxidant a-tocopherol (vitamin E) between PD and controls in brain [ 191 or serum [20] .
Mitochondrial dysfunction in PD
The clue that oxidative stress and mitochondria1 dysfunction may be involved in the cause of dopaminergic cell death in PD came from the study of the mechanism of action of the neurotoxin 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) . MPTP is converted to 1-methyl-Cphenylpyridinium (MPP+) by monoamine oxidase B (MAO-B). MPP+ is a substrate for the dopamine re-uptake pathway and so is concentrated into dopaminergic neurons. MPP' is then accumulated into mitochondria by an energy-dependent mechanism, where it selectively inhibits NADH CoQ, reductase (complex I) of the respiratory chain (see [21] for review). The inhibition of complex I, and the consequent fall in ATP levels, is thought to be the mechanism of MPTP-induced neuronal cell death. However, there is evidence that oxidative damage may be involved in MPTP toxicity. Firstly, transgenic mice showing increased activity for human cytosolic SOD are more resistant to MPTP [ 221. Secondly, MA0 inhibitors block the enhanced formation of hydroxyl radicals by 2'-CH,-MPTP in rat striatum [23] .
There is an important reciprocal relationship between respiratory chain inhibition and free radical generation. The respiratory chain is recognized as a major source of superoxide in the cell [24] superoxide generation is increased by inhibition of complexes I, I11 or IV [25, 261. Conversely, oxidative stress can inhibit respiratory chain enzyme activities, although which of the four complexes is most sensitive to oxidative damage is a subject of some controversy [27, 28] and is probably dependent upon the systems studied.
The precise mechanism by which MPP+ inhibits complex I is unknown. Competitive binding experiments suggest that MPP+ binds at or near the same site as rotenone and piericidin [29] . Incubation of MPP + with submitochondrial particles results in partial inhibition of enzyme activity which can be easily reversed by washing. Longer incubation under certain conditions can, however, lead to more profound inhibition which is mostly irreversible [30] . This irreversible inhibition of complex I by MPP+ is specific and can be prevented by coincubation with free radical scavengers. This suggests that the initial inhibition of complex I by MPP+ leads to the release of free radicals which in turn specifically target complex I to induce a more profound and irreversible defect. This mechanism may have implications for the free radical damage seen in PD (see below).
The finding of specific 30-38% complex I deficiency in PD substantia nigra provided a direct link between the idiopathic disease and the neurotoxic model [31] . As the assays were performed on tissue homogenates, this represents the complex I activity of glial as well as neuronal components. Immunohistochemistry with respiratory chain antibodies did suggest some decreases in complex I staining of PD neurons, but glial staining was low in both PD and control nigras [32] . Studies so far have shown that the complex I defect is not present in any other brain area, thus indicating a high degree of anatomic selectivity [33] . The absence of complex I deficiency in substantia nigra from MSA patients implies that this defect is not a result of neuronal degeneration [33] . The fact that these patients had taken L-DOPA in similar quantities for comparable periods to PD patients also suggests that nigral complex I deficiency is not related to drug therapy. Reports on mitochondria1 function in PD skeletal muscle [34-361 and platelets [36-391 are conflicting but evidence is accruing for a mild ( -16%) deficiency of complex I in platelet mitochondria from PD patients. This observation may seem to be at odds with the apparent specificity of the defect to the substantia nigra within the central nervous system. However, platelets have particular characteristics in common with dopaminergic neurons (MAO-B, ability to concentrate MPP+ ) [40] , which might render them particularly susceptible to endogenous or exogenous circulating toxins.
It is useful to establish the sequence of events involving iron overload, oxidative stress and mitochondrial dysfunction in order to determine the relative importance of these abnormalities in the death of dopaminergic neurons and the aetiology of PD. The morphological examination of a series of control brains has established that approximately 10% of individuals over 60 years of age have changes compatible with early (asymptomatic) PD. These brains may therefore contain the earliest biochemical changes that may lead to the neuronal loss of PD. Such brains do not show any changes in iron or ferritin levels. They do, however, show a small but significant decrease in reduced glutathione. Marsden, unpublished work). These findings suggest that free radical damage in asymptomatic PD is limited and does not involve iron. The recent finding that a decrease in reduced glutathione levels may be induced by complex I inhibition further complicates the interpretation of these results [41] .
The need to examine the relationship of the three candidates for dopaminergic cell death (iron, free radicals, complex I deficiency) in vivo has led to the use of dopaminergic cell lines (PC12 cultures) as a model for the biochemical changes that may occur in the substantia nigra. Using media which render these cells more oxidatively dependent produces a system that more closely resembles neurons. Iron loading of these cells over 48 h with ferric ammonium citrate can simulate the high iron concentration of the substantia nigra in PD and reduce cell growth rates without causing cell death unpublished work). The increased intracellular iron content was approximately twice that found in P D substantia nigra; at least 62% of this iron was represented by forms of non-haem iron other than the iron-ferritin complex. This resulted in oxidative damage and decreased glutathione levels. Mild but significant reductions were found in complex I (15% decrease) and complex IV (21% decrease) activities. The severity and pattern of respiratory chain enzyme dysfunction with iron overload was therefore different from that found in PD substantia nigra. The implication of these results is that iron overload may cause oxidative damage to the cell but does not cause the specific inhibition of complex I observed in PD. This poses the question of why, in the presence of the high iron concentration in PD substantia nigra, there is no complex IV deficiency. One possible explanation is that there is indeed sufficient ferritin to bind the excess iron in PD.
Genetic factors
Any genetic factors involved in the complex I deficiency in PD must take account of the possible contribution of both mitochondrial and nuclear genomes. Mitochondria1 DNA analysis by Southern blotting has not demonstrated a significant accumulation of deletions greater than 200 base pairs in size [42, 431 . Polymerase chain reaction amplification of PD substantia nigra with age-matched controls has demonstrated that the 5 kb 'common' deletion seen in other mitochondrial pathologies is present only in low concentrations and is not increased in PD [44] . Immunoblotting of PD substantia nigra with complex I antibodies has produced conflicting results. One study has shown a decrease in certain low-molecular-mass complex I subunits [45] , while another showed no significant difference in polypeptide profiles between PD and controls [ 3 13.
Summary
The precise relationship of the complex I deficiency in PD to the dopaminergic cell death and aetiology of this disorder is as yet unknown. However, evidence is accruing that this mitochondrial defect may play a central role in the cascade of events that terminates in nigral neuronal loss. Further work needs to be carried out to determine the molecular mechanisms that underlie the complex I deficiency as these may provide important indicators to the ultimate cause of PD. This may involve a genetic abnormality of complex I that may convey a susceptibility to developing PD. Alternatively, exogenous or endogenous toxic agents may target nigral complex I along pathways similar to those recognized for MPTP. A combination of a genetic predisposition in addition to an environmental precipitant has gained substantial support as an explanation for the cause of PD.
